Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vytorin/Inegy ezetimibe/simvastatin: Phase III ongoing

The partners said an independent panel of clinical and biostatistics experts recommended "focusing the primary endpoint" of the double-blind Phase III ENHANCE trial "to the common

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE